SEC Form 4 · accession 0001213900-26-085188
Jasper Therapeutics, Inc. · JSPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Judith Anne Shizuru
Director
Period of report
Jul 31, 2026
Accepted (ET)
Aug 4, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001788028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to BuyF1 | $0.63 | Jul 31, 2026 | A | 7,500 | A | Jul 31, 2027 | Jul 31, 2036 | Voting Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.